MedTrace Logo

Prolonged Daily Temozolomide for Low-Grade Glioma

NCT00165360 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2009-11-02

No results posted yet for this study

Summary

The purpose of this trial is to determine the effects (good and bad) temozolomide has on patients with low-grade glioma. It will also determine whether temozolomide is effective in preventing or delaying future tumor growth.

Conditions

Interventions

DRUG

Temozolomide

Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    collaborator OTHER

  • University of Virginia

    collaborator OTHER

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Patrick Wen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2006-12-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165360 on ClinicalTrials.gov